Filing Details
- Accession Number:
- 0001012975-19-000242
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-03-14 18:57:03
- Reporting Period:
- 2019-03-12
- Accepted Time:
- 2019-03-14 18:57:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1556263 | Syros Pharmaceuticals Inc. | SYRS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1219039 | Keith Crandell | C/O Arch Venture Fund Vii 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1219042 | Robert Nelsen | C/O Arch Venture Fund Vii 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1219043 | Clinton Bybee | C/O Arch Venture Fund Vii 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1402439 | Arch Venture Fund Vii, L.p. | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1544443 | Arch Venture Partners Vii, Llc | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1544444 | Arch Venture Partners Vii, L.p. | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-03-12 | 40,092 | $7.37 | 4,432,462 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-03-13 | 81,591 | $7.89 | 4,350,871 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-03-13 | 2,820 | $8.20 | 4,348,051 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-03-14 | 43,000 | $8.15 | 4,305,051 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Reflects aggregation of stock sales within the range of $7.27 to $7.51. ARCH Venture Fund VII, L.P. ("ARCH Fund VII") can provide detailed support upon request.
- Reflects aggregation of stock sales within the range of $7.19 to $8.185. ARCH Fund VII can provide detailed support upon request.
- Reflects aggregation of stock sales within the range of $8.19 to $8.22. ARCH Fund VII can provide detailed support upon request.
- Reflects aggregation of stock sales within the range of $7.915 to $8.39. ARCH Fund VII can provide detailed support upon request.
- Beneficial ownership consists of 4,305,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Billionaire Hedge Funds
